VeriPark Partners with Leading Canadian Financial Institutions Coalition to Redefine Digital Banking

This collaboration will deliver a Canadian-focused digital banking product tailored to the distinct needs of Canadians. Combining global and Canadian codebases, the solution allows institutions to maintain their identities while developing additional features to differentiate themselves.
"The partnership with VeriPark represents a uniquely Canadian solution that combines local expertise with global best practices," said
The coalition selected VeriPark for its Canadian-centric product development, enhanced security and compliance, support for open banking frameworks and commitment to ongoing managed services. Powered by Microsoft Azure, the solution ensures adaptability, efficiency and long-term support.
The solution integrates with Central 1's payment and fraud management systems while supporting compatibility with other payment platforms, providing flexibility for institutions.
Coalition members gain:
- A Canadian-focused solution enhanced by global best practices.
- The ability to compete with larger banks while maintaining independence.
- A solution validated by a year-long assessment, ensuring innovation and long-term support through Microsoft's technology stack.
Institutions can contact
"The financial services sector is constantly evolving, and this partnership offers a unique opportunity to shape the future of digital banking in
VeriPark is a global solutions provider enabling financial institutions to become digital leaders with its AI-Powered Customer Experience Suite.
Logo: https://mma.prnewswire.com/media/2447880/VeriPark_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/veripark-partners-with-leading-canadian-financial-institutions-coalition-to-redefine-digital-banking-302354208.html
SOURCE VeriPark
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer
- Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study
- Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share